Hypertriglyceridemic waist increased risk of inappropriate glucose control in patients with coronary heart disease

Q Medicine Clinical Lipidology Pub Date : 2014-10-01 DOI:10.2217/clp.14.49

O. Mayer, J. Seidlerová, J. Bruthans, Katarína Timoracká, Petra Vágovičová, J. Vaněk, P. Wohlfahrt, J. Filipovský, R. Cífková

引用次数: 1

Abstract

Abstract Aim: The definition of metabolic syndrome (MetSy) in patients with coronary heart disease (CHD) remains problematic because of concomitant treatment. We speculate, which definition is suitable in terms of long-term glycemic status. Methods: We analyzed 979 patients with stable CHD. Four different MetSy definitions were used: ‘standard Adult Treatment Panel III (ATP)’, ‘modified ATP’ (not using antihypertensive treatment as an alternative criterion), ‘atherogenic dyslipidemia’ or ‘hypertriglyceridemic waist’. Results: The presence of ‘hypertriglyceridemic waist’ was associated with almost twofold higher risk (OR 1.79; 95% CI: 1.19 – 2.68) of hemoglobin A1c ≥48. Predictive power of standard or modified ATP definitions diminished after adjustment. Conclusion: In CHD patients, the simplified MetSy definition using ‘hypertriglyceridemic waist’ provides better prediction for glycemic control than ATP definition.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

高甘油三酯血症腰增加冠心病患者血糖控制不当的风险

摘要目的:冠心病(CHD)患者代谢综合征(MetSy)的定义由于伴随治疗而存在问题。我们推测，哪个定义适合长期血糖状态。方法:对979例稳定期冠心病患者进行分析。使用了四种不同的MetSy定义:“标准成人治疗组III (ATP)”、“改良ATP”(不使用降压治疗作为替代标准)、“动脉粥样硬化性血脂异常”或“高甘油三酯血症腰”。结果:“高甘油三酯血症腰”的存在与几乎两倍的高风险相关(OR 1.79;95% CI: 1.19 ~ 2.68)，血红蛋白A1c≥48。标准或修改后的ATP定义的预测能力在调整后降低。结论:在冠心病患者中，使用“高甘油三酯血症腰”的简化MetSy定义比ATP定义更能预测血糖控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.